Search

The book is a compact yet comprehensive practical resource that highlights all must-know information on non-alcoholic fatty liver disease (NAFLD). Covering the major issues dominating the field, this book offers a broad vision on NAFLD using key data for a deep and thorough understanding of the latest diagnostic methods, treatment options, potential complications, and disease management strategies to improve patient outcomes. The volume bridges the trans-disciplinary divide between hepatologists, cardiologists, nephrologists, psychiatrists, oncologists and dermatologists in order to cover the complex management of NAFLD in a single volume. It operates under a modern definition of NAFLD that acknowledges the range of presentations related to extrahepatic complications that hepatologists see in daily practice, while also delving into unanswered questions and future directions regarding treatment options. Offering practical, clinical guidance in addition to capturing the new promising therapeutic approaches in the pipeline, this book is an essential reference for clinicians, researchers and students.

The goal of this book is to promote awareness of non-alcoholic fatty liver disease (NAFLD) – which is rapidly replacing viral hepatitis as the leading cause of chronic liver disease in Europe, North and South America and Asia – and to share the latest information on evolving approaches to diagnosis and treatment. The book offers a comprehensive overview of the current topics of interest in the field, and provides clinical guidance on NAFLD through a multidisciplinary approach based on the latest scientific understanding of this multisystemic disease, involving the expertise of specialists including hepatologists, diabetologists, and cardiologists. The respective contributions address various aspects, including the newly released international guidelines, novel diagnostic modalities, and new experimental drugs. The work will appeal to a broad readership, from residents in internal medicine to specialists.​

This volume covers a state-of-the-art illustration of recent discoveries concerning obesity-related fatty liver diseases and liver cancer. The contents are extensive and comprehensive. It brings important topics in the field all together under one umbrella, from epidemiology and etiology, molecular pathogenesis, cellular biology, epigenetics, immunology, microbiology, animal models to therapeutic approaches and treatments. All the book contributors are leading experts in the field. It will appeal to researchers, clinicians and graduate students in obesity, fatty liver diseases, GI/Liver cancer field. It may also yield benefits for pharmaceutical companies with regard to drug discovery.

Non-alcoholic fatty liver disease (NAFLD) is a common cause of elevated liver enzymes and chronic liver disease in Western countries. NAFLD is characterized by elevated liver enzymes in the absence of alcohol consumption and secondary causes of liver disease. It is an independent predictor of future risk of cardiovascular diseases, type 2 diabetes and metabolic syndrome (hypertension, abdominal obesity, dyslipidemia, glucose intolerance). This book is a quick reference guide for medical students and professionals about NAFLD. Readers will find a summary of epidemiology, clinical features, diagnosis, imaging techniques, histopathology, and disease management. The book also presents information about NAFLD linked with hepatocellular carcinoma and guidelines for treating NAFLD in pediatric patients. Each chapter presents information in a simple, structured manner making this text an ideal handbook for supplementing hepatology modules in medical curricula.

Alles, was derzeit über die Fettleber bekannt ist, und was Sie dagegen tun können: Anders als viele denken, ist die Fettleber nicht nur eine Folge von Alkoholkonsum: Noch öfter tritt die Erkrankung bei übergewichtigen Menschen auf. Bei ihnen kommen häufig Risikofaktoren wie erhöhtes Cholesterin, Bluthochdruck und Insulinresistenz zusammen. Wenn sich die Leber entzündet, kann das ernste Folgen haben, bis hin zu Leberzirrhose oder Leberkrebs. Mit diesem Buch gibt die Patientenorganisation Deutsche Leberhilfe e. V. einen Überblick darüber, was derzeit über die Fettleber bekannt ist. Das Expertenteam aus Fachärzten, Patientenberatern und Ernährungsexperten beantwortet drängende Fragen: Wie entsteht eine Fettleber? Was sollte getestet werden? Wie wird sie behandelt? Außerdem gibt es viele schmackhafte Rezeptvorschläge – denn einer Fettleber entgegenzuwirken ist nicht nur gesund, sondern soll auch Spaß machen. Das spricht für diesen Ratgeber: - Expertenteam: Fachärzte, Ökotrophologen und Berater der Patientenorganisation. Deutsche Leberhilfe e. V. liefern zuverlässige Antworten - Alle Maßnahmen, die einer Fettleber entgegenwirken, werden übersichtlich dargestellt.

Non-alcoholic fatty liver disease, or NAFLD, represents a spectrum of pathologic liver histologic findings ranging from the simple accumulation of fat, known as steatosis, to nonalcoholic steatohepatitis and cirrhosis. It is estimated that NAFLD in all of its forms would have a 20% prevalence worldwide, but the evidence suggests a higher rate for developed countries, exceeding 30% for the US general population. Major risk factors for NAFLD, such as ageing, obesity and insulin resistance, are projected to increase in the following decades, causing the prevalence and relevance of NAFLD to rise in the future. In obese populations and type 2 diabetes patients, the prevalence of this disease exceeds 70%. NAFLD has been called the “silent epidemic” for its lack of symptoms, relatively complex diagnosis and its deleterious effects. The association between NAFLD with cardiovascular diseases, energy metabolism disorders and polycystic ovarian syndrome has promoted the inclusion of this liver pathology within the metabolic syndrome. From a biochemical point of view, current evidence suggests the existence of a bidirectional causal relationship between NAFLD and oxidative stress, where various alterations energy metabolism and important inflammatory components are involved. An abnormal glucose and fatty acid metabolism lead to glucotoxicity and lipotoxicity, respectively, which promote oxidative stress through different pathways. Oxidative stress induces the expression of pro-inflammatory mediators, including transcription factors and cytokines, which trigger an immune activation, a key step in the transition from simple steatosis to steatohepatitis. An early diagnosis and optimal therapy are essential for NAFLD treatment. First-line treatment of NAFLD focuses on lifestyle changes. Weight reduction through an increase in physical activity and/or nutritional management is considered safe and effective, but pharmacological management of common comorbidities such as hyperglycemia, dyslipidemias and hypertension are also essential. The key role of oxidative stress in NAFLD pathophysiology suggests that antioxidant interventions based in natural substances such as polyphenols would be effective. Recently, it was shown that the antioxidant properties of these compounds are beyond their free radical scavenging. This book presents an update of research advances contributing to a better understanding of relevant clinical models of NAFLD, particularly, the disorder in energy metabolism and the role of oxidative stress. It also highlights the clinical and pathophysiological association between NAFLD and the metabolic syndrome, and presents an overview of current diagnosis and treatment and the future avenues for the management of this disease.

This volume is the first text to concisely yet comprehensively cover developments for both alcoholic and nonalcoholic fatty liver disease in an organized fashion. Aspects of these two diseases covered in the book include global epidemiology and risk factors, pathogenesis, animal models, hepatic and extra-hepatic malignancies, treatment models, and current and emerging therapies. Written by experts in the field, Alcoholic and Non-Alcoholic Fatty Liver Disease: Bench to Bedside is a valuable resource for gastroenterologists, pathologists, and hepatologists who treat patients with alcoholic and nonalcoholic fatty liver disease.

Internationally renowned experts present topics related to obesity, nutrition, and liver disease in this issue. In the first article, the epidemiology of obesity and its association with liver disease are covered. The following two articles focus on the roles that visceral adipose tissue and microbiota potentially play in the pathogenesis of obesity-related liver disease. The next article focuses on the hepatic pathology seen in patients with obesity-related liver disease and those with malnutrition. The next five articles are focused on NAFLD and provide in-depth data on the natural history and treatment strategies for patients with NAFLD. The next six articles deal with the impact of obesity on other liver diseases and on special populations including children and liver-transplant recipients. The final article provides the most updated information regarding genomics and genetic targets that may provide better prognostic and diagnostic biomarkers and more personalized treatment targets for patients with NAFLD. Cutting-edge information in this issue will help readers gain better understanding of the natural history and pathogenesis of primary and secondary liver diseases associated with obesity. As the information about obesity-related liver disease expands, clinicians will be able to provide more targeted therapeutic options for these patients and develop more accurate diagnostic and prognostic biomarkers.

In the last few years, human metabolic disorders have become some of the most prevalent and prejudicial diseases worldwide. Hepatic steatosis, among many health problems, has several risk factors related to the disease prognosis such as obesity, nutritional problems, diabetes, hypertension, hyperuricemia and even sleep apnea. Alcohol abuse also can lead to a severe liver-steatosis state. The progression of hepatic steatosis can lead to complications such as cryptogenic cirrhosis and hepatocellular carcinoma. Drug therapy has instead been focused on the mitigation of risk factors, however, new potential therapeutic perspectives are being discussed. This book presents the origins, diagnosis and epidemiology of hepatic steatosis with new perceptions. The authors also aim to show the molecular basis and signaling involved in liver disorders, discussing the inflammatory process, lipid metabolism and angiogenesis mechanisms. The role of nutrition in the treatment and development of steatosis was also presented and new advances were highlighted. Recent studies revealed the need for the use of bariatric surgery, functional foods and the modulation of endogenous systems, such as the sirtuins and renin-angiotensin systems, to treat liver disease. In this context, we aimed to introduce, review and discuss one of the most widespread metabolic disorders in the world: hepatic steatosis and its repercussions.

Fatty liver disease is the most common type of liver disease seen in the world today, affecting 20% of the population. Written by experts and based on the most current information available,'Healing Fatty Liver Disease'is the indispensable guide for anyone living with fatty liver disease. There is extensive information on the causes of NAFLD, the symptoms and signs, and treatment options. Because diet plays a major role in managing the condition, 100 specially selected recipes are also included.

Insulin resistance (IR) and metabolic syndrome are associated with the pathogenesis and progression of non-alcoholic fatty liver disease (NAFLD). It encompasses a spectrum of hepatic pathology, ranging from simple steatosis in its most benign form (fatty liver), going through nonalcoholic steatohepatitis (NASH) in its intermediate form, until cirrhosis and hepatocellular carcinoma, its most advanced forms. This new book presents current research on the background of fatty acid oxidation; hepatic steatosis and its progression to NASH and cirrhosis; fibrosis and myofibroblastic cells differentiation; methods of diagnosis; clinical features and laboratory tests and, finally, rodent NAFLD and NASH models.